MX2016012845A - Vacuna contra el virus de la diarrea epidemica porcina. - Google Patents

Vacuna contra el virus de la diarrea epidemica porcina.

Info

Publication number
MX2016012845A
MX2016012845A MX2016012845A MX2016012845A MX2016012845A MX 2016012845 A MX2016012845 A MX 2016012845A MX 2016012845 A MX2016012845 A MX 2016012845A MX 2016012845 A MX2016012845 A MX 2016012845A MX 2016012845 A MX2016012845 A MX 2016012845A
Authority
MX
Mexico
Prior art keywords
epidemic diarrhea
porcine epidemic
diarrhea virus
vaccine
virus vaccine
Prior art date
Application number
MX2016012845A
Other languages
English (en)
Inventor
B Roof Michael
Martin Vaughn Eric
M Murphy Jordan Dianna
Rae Patterson Abby
Gilbert Victoria Joseph
Alejandro Hernández Luis
V Iyer Arun
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Publication of MX2016012845A publication Critical patent/MX2016012845A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20063—Methods of inactivation or attenuation by chemical treatment

Abstract

La presente invención se refiere a una vacuna para proteger un cerdo contra enfermedades asociadas al virus de la diarrea epidémica porcina. La vacuna incluye comúnmente PEDV inactivado/suprimido (por ejemplo, virus de PED químicamente inactivado) y/o antígeno de PEDV recombinante y un adyuvante. También se proporcionan métodos para proteger cerdos contra enfermedades asociadas a PEDV y métodos para producir la vacuna contra el virus de la diarrea epidémica porcina.
MX2016012845A 2014-04-03 2015-03-30 Vacuna contra el virus de la diarrea epidemica porcina. MX2016012845A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461974722P 2014-04-03 2014-04-03
PCT/US2015/023284 WO2015153425A1 (en) 2014-04-03 2015-03-30 Porcine epidemic diarrhea virus vaccine

Publications (1)

Publication Number Publication Date
MX2016012845A true MX2016012845A (es) 2017-01-11

Family

ID=52829435

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012845A MX2016012845A (es) 2014-04-03 2015-03-30 Vacuna contra el virus de la diarrea epidemica porcina.

Country Status (10)

Country Link
US (2) US9950061B2 (es)
EP (1) EP3125932A1 (es)
JP (2) JP6395855B2 (es)
KR (1) KR20160132494A (es)
CN (2) CN112316129A (es)
AU (1) AU2015241107B2 (es)
CA (1) CA2943816A1 (es)
EA (1) EA201691993A1 (es)
MX (1) MX2016012845A (es)
WO (1) WO2015153425A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2938356B1 (en) * 2012-12-28 2020-05-13 Boehringer Ingelheim Vetmedica GmbH Immunogenic composition comprising mycoplasma antigens
US10280199B2 (en) 2014-02-07 2019-05-07 Phibro Animal Health Corporation Coronavirus proteins and antigens
WO2015138455A1 (en) 2014-03-11 2015-09-17 Regents Of The University Of Minnesota Porcine epidemic diarrhea virus vaccines and methods of use thereof
AU2015241107B2 (en) 2014-04-03 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Porcine epidemic diarrhea virus vaccine
US9713639B2 (en) * 2014-05-19 2017-07-25 Merial, Inc. Recombinant spike protein subunit based vaccine for porcine epidemic diarrhea virus (PEDV)
PT3166634T (pt) 2014-07-11 2021-09-29 Zoetis Services Llc Composições de vacina inovadoras para vírus da diarreia epidémica suína
US20160008457A1 (en) * 2014-07-11 2016-01-14 Merial, Inc. Inactivated Vaccine for Porcine Epidemic Diarrhea Virus (PEDV)
WO2016038194A1 (en) * 2014-09-12 2016-03-17 Intervet International B.V. Vaccine for use in protecting a pig against porcine endemic diarrhea virus
WO2016118880A1 (en) * 2015-01-23 2016-07-28 The Trustees Of The University Of Pennsylvania Immunogenicity of an optimized synthetic consensus dna vaccine for porcine epidemic diarrhea virus
CA2977980C (en) 2015-02-27 2022-04-26 Iowa State University Research Foundation, Inc. Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
TW201731525A (zh) * 2015-11-25 2017-09-16 薩斯喀徹溫大學 治療、預防及診斷豬流行性下痢病毒感染之方法
CN107304416A (zh) * 2016-04-19 2017-10-31 北京大伟嘉生物技术股份有限公司 一株猪流行性腹泻病毒及其培养方法和应用
JP6253210B1 (ja) * 2016-08-17 2017-12-27 一般財団法人日本生物科学研究所 豚流行性下痢の予防又は治療方法、ワクチン、及びワクチンキット
MY191895A (en) 2016-11-03 2022-07-18 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
JP2020506915A (ja) * 2017-01-30 2020-03-05 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド ブタコロナウイルスワクチン
CN108822191B (zh) * 2017-04-13 2023-07-07 浙江海隆生物科技有限公司 猪流行性腹泻病毒s蛋白及其亚单位疫苗及其制备方法和应用
WO2018188639A1 (zh) * 2017-04-13 2018-10-18 浙江海隆生物科技有限公司 猪流行性腹泻病毒s蛋白及其亚单位疫苗及其制备方法和应用
CN107698665B (zh) * 2017-10-26 2020-09-15 浙江大学 一种抗病毒多肽、编码基因、载体、宿主菌及应用
CN108118032A (zh) * 2017-12-12 2018-06-05 新疆希普生物科技股份有限公司 猪流行性腹泻病毒2型毒株的培养及灭活疫苗的研制
CN108219000B (zh) * 2018-01-17 2021-05-25 北京市农林科学院 一种pedv保护性抗原蛋白及其在乳酸菌中表达的方法
CN108362871A (zh) * 2018-02-07 2018-08-03 远见生物科技（上海）有限公司 用于中性粒细胞胞外诱捕网检测的试剂盒及检测方法
CN108486067B (zh) * 2018-02-11 2022-03-15 黑龙江正康生物技术股份有限公司 猪流行性腹泻病毒变异株及其制备的灭活疫苗和应用
US20210162039A1 (en) * 2018-05-11 2021-06-03 Kansas State University Research Foundation Multiepitope fusion antigens for vaccination and methods of making and using such antigens
CN109161534A (zh) * 2018-09-14 2019-01-08 中国农业科学院兰州兽医研究所 一株基因型2a的猪流行性腹泻病毒毒株及其在制备猪流行性腹泻疫苗中的应用
CN109022372B (zh) * 2018-09-19 2022-03-29 天康制药(苏州)有限公司 一种猪流行性腹泻病毒的培养方法
CN112867506A (zh) * 2018-09-20 2021-05-28 勃林格殷格翰动物保健有限公司 抗猪流行性腹泻的鼻内载体疫苗
EP3852797A1 (en) * 2018-09-20 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Modified pedv spike protein
CN110967480A (zh) * 2018-09-28 2020-04-07 洛阳普泰生物技术有限公司 一种猪流行性腹泻病毒IgA抗体ELISA试剂盒的制备及应用
US11564405B2 (en) 2019-03-04 2023-01-31 Novus International, Inc. Reducing the risk of viral infection due to viral contaminated feed
CN110135157B (zh) * 2019-04-04 2021-04-09 国家计算机网络与信息安全管理中心 恶意软件同源性分析方法、系统、电子设备及存储介质
KR102213745B1 (ko) * 2019-04-16 2021-02-09 주식회사 바이오앱 돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법
US11413347B2 (en) * 2019-09-02 2022-08-16 Reber Genetics Co., Ltd. Vaccine composition and method of preventing porcine epidemic diarrhea virus infection in swine
EP4138901A1 (en) * 2020-05-11 2023-03-01 University of Virginia Patent Foundation Compositions and methods for inducing immune responses against class i fusion protein viruses
CN112063620A (zh) * 2020-06-16 2020-12-11 中国人民解放军陆军军医大学 抑制猪流行性腹泻病毒M基因表达的shRNA
CN112680421B (zh) * 2021-02-01 2022-09-13 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 具有广谱性中和猪流行性腹泻病毒的单克隆抗体及其应用
CN113292659B (zh) * 2021-05-19 2022-06-17 江苏省农业科学院 重组蛋白和猪流行性腹泻疫苗组合物
KR20240034182A (ko) 2021-06-03 2024-03-13 마젠 애니멀 헬스 인코포레이티드 사이토카인 수준을 변경하고 갓 태어난 돼지에게 수동 면역을 제공하기 위한 코로나바이러스 스파이크 단백질의 경구 투여
CN113583141B (zh) * 2021-08-04 2023-03-03 江西农业大学 猪流行性腹泻病毒Nsp9蛋白、含该Nsp9蛋白的融合蛋白及其制备方法和应用
CN114395574B (zh) * 2022-01-18 2023-08-11 长沙爱科博生物科技有限公司 一种猪流行性腹泻病毒融合蛋白及其编码基因与应用
CN116024244B (zh) * 2022-08-04 2023-09-22 长沙爱科博生物科技有限公司 一种融合蛋白基因及其应用
CN115957349B (zh) * 2022-10-08 2024-04-05 华中农业大学 激活猪的pja1基因表达的制剂在制备猪抗猪流行性腹泻病毒感染药物中的应用
CN117143207B (zh) * 2023-09-05 2024-03-12 湖南派智生物科技有限公司 一种重组表位蛋白、编码基因、重组质粒、制备方法、工程菌及应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4615697A (en) 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1990001543A1 (fr) 1988-07-29 1990-02-22 Intracel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1990011092A1 (en) 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
WO1995020660A2 (en) 1994-01-27 1995-08-03 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
KR0179947B1 (ko) 1994-05-06 1999-03-20 윤인중 돼지 유행성 설사병과 전염성 위장염 바이러스 혼합 사독 유성백신의 제조방법
KR0143239B1 (ko) 1994-12-22 1998-07-01 김광희 돼지 유행성 설사병 예방약 생산을 위한 약독화 바이러스주
EP0871755A1 (en) 1995-03-23 1998-10-21 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
AU737243B2 (en) 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
JP3003989B2 (ja) 1996-09-18 2000-01-31 全国農業協同組合連合会 豚流行性下痢ウイルス（ｐｅｄｖ）感受性細胞の作出法
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
KR100267745B1 (ko) 1998-01-10 2000-11-01 . 돼지 유행성설사병 바이러스의 특이 중화항체 검출방법
DK1071407T3 (da) 1999-01-18 2014-10-20 Lg Life Sciences Ltd Lipofile mikropartikler indeholdende et proteinlægemiddel eller et antigen og formulering omhandlende samme
KR100432977B1 (ko) 2001-04-19 2004-05-28 녹십자수의약품(주) 돼지 아미노펩티다제 엔을 이용한 돼지 유행성 설사병바이러스의 배양방법 및 그 생독 백신
CA2453880A1 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
JP3812814B2 (ja) 2001-10-19 2006-08-23 株式会社微生物化学研究所 動物用多価オイルアジュバントワクチン
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
KR100492820B1 (ko) 2002-04-16 2005-05-31 양문식 돼지 유행성 설사병 바이러스 중화 에피토프 및 이의 이용
US20070286872A1 (en) 2003-04-23 2007-12-13 Vanderbilt University Live Attenuated Nidovirus Vaccines
KR100502008B1 (ko) 2003-04-29 2005-07-18 녹십자수의약품(주) 약독화된 돼지 유행성설사병 바이러스, 그를 포함하는면역원성 조성물 및 상기 바이러스를 검출하는 방법
US7527967B2 (en) 2003-11-25 2009-05-05 Academia Sinica Recombinant baculovirus and virus-like particle
KR100622399B1 (ko) * 2004-01-14 2006-09-18 대한민국 불활화시킨 ｔｇｅｖ 및 ｐｅｄｖ을 함유하는 혼합불활화백신 및 그 제조방법
ATE526034T1 (de) 2004-01-21 2011-10-15 Merial Ltd Verbesserte inaktivierte fcv-vakzinen
CN1323718C (zh) 2004-03-15 2007-07-04 中国农业科学院兰州兽医研究所 一种利用植物油佐剂制备动物病毒性、细菌性疫苗的方法
US7452542B2 (en) 2004-05-21 2008-11-18 Vanderbilt University Live attenuated coronavirus vaccines
CN1827172A (zh) 2005-04-27 2006-09-06 中国人民解放军军事医学科学院军事兽医研究所 以犬ⅱ型腺病毒为载体的猪病毒性传染病基因重组活疫苗及生产工艺
KR100737434B1 (ko) 2006-03-10 2007-07-09 대한민국 돼지전염성위장염바이러스, 유행성설사바이러스 및로타바이러스의 혼합생백신 및 이를 이용한 백신접종방법
RU2357755C2 (ru) 2006-09-27 2009-06-10 Виталий Александрович Сергеев Инактивированная вакцина против трансмиссивного гастроэнтерита свиней (тгс) и эпизоотической диареи свиней (эдс) из кишечного вируса искусственно зараженных безмолозивных поросят (вакцина тгэдс)
KR100773141B1 (ko) 2006-10-26 2007-11-02 재단법인서울대학교산학협력재단 돼지 유행성 설사 바이러스 ｏｒｆ3 폴리펩티드 변이체,그를 코딩하는 핵산, ｏｒｆ3 변이체 및 변이 유전자를이용하여 야생형과 약독화형 ｐｅｄｖ를 구별하는 방법 및야생형과 약독화형 ｐｅｄｖ를 구별하기 위한 키트
KR100773241B1 (ko) * 2006-12-06 2007-11-05 주식회사한국야쿠르트 돼지 유행성 설사병 바이러스에 대한 중화항원 및 그 응용
CN101117627B (zh) * 2007-02-01 2010-07-14 中国农业科学院哈尔滨兽医研究所 猪流行性腹泻病毒弱毒疫苗株及其应用
CN101491673A (zh) 2008-12-26 2009-07-29 天津瑞普生物技术股份有限公司 猪传染性胃肠炎、猪流行性腹泻和猪轮状病毒的三联疫苗
KR101671528B1 (ko) 2010-12-14 2016-11-01 단국대학교 산학협력단 돼지 유행성 설사병 바이러스의 에피토프와 점막면역보조제를 발현하는 형질전환체 및 이를 포함하는 백신 조성물
KR101680903B1 (ko) 2010-12-14 2016-11-30 단국대학교 산학협력단 돼지 유행성 설사병 바이러스의 에피토프와 로타바이러스 유전자를 발현하는 형질전환체 및 이를 포함하는 백신 조성물
KR20120066555A (ko) 2010-12-14 2012-06-22 단국대학교 산학협력단 돼지 유행성 설사병 바이러스의 에피토프 단백질을 발현하는 형질전환체 및 이를 포함하는 ｐｅｄｖ 백신 조성물
CN102949718B (zh) 2011-08-26 2015-06-17 普莱柯生物工程股份有限公司 猪传染性胃肠炎病毒、猪流行性腹泻病毒和猪轮状病毒的三联活疫苗
CN102399806A (zh) 2011-12-16 2012-04-04 武汉华扬动物药业有限责任公司 猪流行性腹泻s1蛋白融合基因及重组巨大芽孢杆菌和应用
CN102988971B (zh) * 2012-12-04 2014-11-26 山东信得科技股份有限公司 一种猪流行性腹泻病毒基因工程亚单位口服疫苗的制备方法
CN103041385B (zh) 2013-01-29 2014-02-19 齐鲁动物保健品有限公司 一种猪传染性胃肠炎、流行性腹泻二联活疫苗及其制备方法
CN103585625B (zh) * 2013-11-29 2015-12-02 华南农业大学 一种猪流行性腹泻重组杆状病毒基因工程亚单位疫苗及其制备方法与应用
KR101442493B1 (ko) 2014-02-21 2014-09-26 우진 비앤지 주식회사 돼지유행성설사병바이러스 약독화주 및 이를 포함하는 돼지유행성 설사병 백신 조성물
WO2015138455A1 (en) * 2014-03-11 2015-09-17 Regents Of The University Of Minnesota Porcine epidemic diarrhea virus vaccines and methods of use thereof
CN103992989B (zh) * 2014-03-20 2015-02-25 广东海大畜牧兽医研究院有限公司 一种猪流行性腹泻病毒及其应用
AU2015241107B2 (en) 2014-04-03 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Porcine epidemic diarrhea virus vaccine

Also Published As

Publication number Publication date
AU2015241107B2 (en) 2019-10-03
CN107073101A (zh) 2017-08-18
EA201691993A1 (ru) 2017-02-28
US20180207260A1 (en) 2018-07-26
WO2015153425A1 (en) 2015-10-08
EP3125932A1 (en) 2017-02-08
US20150283229A1 (en) 2015-10-08
CN112316129A (zh) 2021-02-05
JP6395855B2 (ja) 2018-09-26
US10702601B2 (en) 2020-07-07
JP2018203757A (ja) 2018-12-27
JP6704964B2 (ja) 2020-06-03
KR20160132494A (ko) 2016-11-18
US9950061B2 (en) 2018-04-24
CA2943816A1 (en) 2015-10-08
CN107073101B (zh) 2020-10-27
AU2015241107A1 (en) 2016-10-06
JP2017511328A (ja) 2017-04-20

Similar Documents

Publication Publication Date Title
MX2016012845A (es) Vacuna contra el virus de la diarrea epidemica porcina.
PH12019501766A1 (en) Porcine coronavirus vaccines
PH12018501602A1 (en) Subunit immersion vaccines for fish
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
PH12019501366A1 (en) Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
PH12019500854A1 (en) Recombinant vectors expressing antigens of avian influenza virus and uses thereof
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
MX2021000951A (es) Composición que contiene vacuna contra la influenza.
MX2021009105A (es) Toxinas apxia, apxiia y apxiiia inactivadas.
PH12017501795B1 (en) Pestivirus vaccines for congenital tremors
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
MX2016009597A (es) Terapias para el influenzavirus a subtipo h7n9.
MX371126B (es) Vacuna para cerdos contra el sindrome reproductivo y respiratorio porcino y lawsonia intracellularis.
MX2019007924A (es) Vacunas contra la influenza.
TH169741B (th) วัคซีนไวรัสก่อโรคท้องเสียที่ระบาดในหมู
TH169741A (th) วัคซีนไวรัสก่อโรคท้องเสียที่ระบาดในหมู
EA202190351A1 (ru) Композиция, входящая в состав вакцины против гриппа
BR112018007918A2 (pt) vacina, uso de antígeno de lawsonia intracellularis inativada, e, método para proteger um animal.
MX2016003470A (es) Identificacion de proteinas inmunogenicas para el control de ectoparasitos.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.

FG Grant or registration